A Study for Patients Who Completed VITALITY-ALS (CY 4031)

NCT02936635 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

280

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG: tirasemtiv

Sponsor

Cytokinetics